Table I.
Drug potency (IC50) and steepness (m) of the dose-response curves obtained after fitting the SRB-based assay data to the median effect equation using the CalcuSyn software.
| NCI-H125 cells | SiHa cells | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Compound | Class | IC50 (μM) | m | Drug range (μM) | IC50 (μM) | m | Drug range (μM) |
| CIGB-300 | CK2-targeted therapy | 69.80 | 1.60 | 6.25–200 | 91.10 | 1.17 | 12.5–400 |
| Paclitaxel | Antimitotic | 0.03 | 0.13 | 0.00002–2 | 0.01 | 0.13 | 0.0002–2 |
| Cisplatin | Alkylating | 9.43 | 2.38 | 0.31–10 | 6.61 | 0.96 | 1.56–25 |
| Doxorubicin | Antitopoisomerase II | 0.14 | 0.76 | 0.00025–25 | 0.13 | 0.35 | 0.00025–25 |
| 5-Fluorouracil | RNA/DNA antimetabolite | 17.83 | 0.40 | 0.02–2000 | 1.28 | 0.11 | 0.02–200 |
The classification of each anticancer compound and the selected range of concentrations for further combinations experiments are also shown. SRB, sulforhodamine B; CK2, casein kinase 2; IC50, half maximal inhibitory concentration.